Covance

Survey: Sponsor’s choice of central lab affects investigator’s satisfaction with trial experience

Monday, December 12, 2011 09:04 AM

The choice of a central lab can greatly affect a principal investigator’s satisfaction level while conducting a clinical trial. 

More... »

Hoffman joins Theorem Clinical Research

Tuesday, November 8, 2011 03:35 PM

Theorem Clinical Research, previously Omnicare Clinical Research, has named Marc Hoffman, MD, senior vice president and general manager for their newly formed pharmaceutical development business unit. In his new role, Hoffman will have strategic oversight for Theorem’s core CRO operation, including project management, clinical monitoring, SMART (site management and patient recruitmenT), and pharmaceutics. He will also oversee the company’s medical operations. 

More... »

Survey: Covance central laboratory services ranks first

Wednesday, November 2, 2011 11:13 AM

Covance central laboratory services ranked first, by a wide margin, in an independent global survey of 550 physician investigators participating in clinical trials. The majority (54%) of the study participants named Covance central laboratory services as their "most preferred" central laboratory, with investigators citing Covance three times more often than the nearest competitor. Investigators also reported having the "best overall relationship" with Covance, rating it 8.4 on a scale of 1 to 10.

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

Kaiser joins Covance

Wednesday, October 19, 2011 10:48 AM

Covance has named Raymond Kaiser, Ph.D., global science leader and vice president for biotechnology services. Kaiser will replace Dr. Carl Martin, who will be retiring from this role, after 35 years with Covance.

More... »

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

Icon and Bristol-Myers Squibb build on strategic partnership, extending it to early-phase work

Monday, September 5, 2011 08:00 AM

Icon and Bristol-Myers Squibb (BMS) have inked a preferred-provider agreement for early-phase development. This constitutes the CRO’s second sizable agreement with BMS; in June 2010, the two formed a strategic partnership, with Icon focused on providing global support for the drug developer’s clinical development pipeline.

More... »

PPD rumored to be in exclusive acquisition talks with D.C.-based private equity firm the Carlyle Group

Monday, August 22, 2011 08:02 AM

While many in the upper echelon of private equity investors have been courting CRO PPD, for now all but one have been shooed away: Washington, D.C.-based Carlyle Group.

More... »

CROs using backlog numbers to put positive spin on less-than-stellar quarterly earnings reports

Monday, August 22, 2011 08:00 AM

Using backlog allows CROs to put a positive spin on what otherwise might be less-than-stellar earnings; while they may not have had the healthiest quarter—or year—financially, they can showcase all of the work that has been promised over the next few quarters in millions, or billions, of dollars.

More... »